| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MNLO | Exit | Menlo Therapeutics Inc. | $0 | – | -1,461,552 | -100.0% | -15.82% | – |
| VRNA | Exit | Verona Pharma PLCsponsored ads | $0 | – | -875,000 | -100.0% | -22.18% | – |
| Exit | Apellis Pharmaceuticals, Inc | $0 | – | -1,790,102 | -100.0% | -62.01% | – |
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Apellis Pharmaceuticals, Inc | 5 | Q4 2018 | 77.1% |
| Verona Pharma PLC | 5 | Q4 2018 | 22.2% |
| Menlo Therapeutics Inc. | 4 | Q4 2018 | 33.9% |
| Nabriva Therapeutics PLC | 3 | Q2 2018 | 12.6% |
View venBio Partners L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-02-14 |
| 13F-HR | 2018-11-14 |
| 13F-HR | 2018-08-14 |
| 13F-HR | 2018-04-25 |
| 13F-HR | 2018-04-25 |
View venBio Partners L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.